Competitive intelligence on
small-molecule drugs and
the 80,000 global patents
covering them

Start your free trial now

No commitment — No credit card required

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: AGGRENOX

« Back to Dashboard

Summary for Tradename: AGGRENOX

Suppliers: see list4

Clinical Trials for: AGGRENOX

Drug-drug Interaction Study of Aggrenox and Omeprazole in Normal Volunteers
Status: Completed Condition: Healthy

PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes
Status: Completed Condition: Stroke

JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme
Status: Completed Condition: Cerebrovascular Accident

Pharmacokinetics of Dipyridamole Administered as Aggrenox® (Dipyridamole Extended Release Plus Aspirin) Capsule Versus Dipyridamole Immediate Release Plus Aspirin Following Alteration of Stomach pH
Status: Completed Condition: Healthy

Headache Study to Compare Aggrenox Full Dose and Reduced Dose
Status: Completed Condition: Cerebrovascular Accident

EARLY 3-months Aggrenox Treatment Started Within 24 Hrs of Ischemic Stroke Onset vs. After One Week 100 mg ASA
Status: Completed Condition: Cerebrovascular Accident

Tolerability of Asasantin in Healthy Female and Male Subjects
Status: Completed Condition: Healthy

Vascular Access Clinical Trials Data Coordinating Center
Status: Completed Condition: Kidney Failure

Treatment of Supine Hypertension in Autonomic Failure
Status: Recruiting Condition: Hypertension

Mechanism of Dipyridamole Action in Platelets: in Vivo Study With Healthy Volunteers
Status: Completed Condition: Healthy

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Boehringer Ingelheim
aspirin; dipyridamole
CAPSULE, EXTENDED RELEASE;ORAL020884Nov 22, 1999RXYes6,015,577<disabled><disabled>
This preview shows a limited data set
Subscribe for full access , or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: AGGRENOX

Drugname Dosage Strength RLD Submissiondate
aspirin and dipyridamoleExtended-release Capsules25 mg and 200 mgAggrenox2/1/2007
« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology